Cardiac troponin I is currently considered to be the gold standard biomarker test for myocardial infarction. Moreover, cTnI measurements by a new generation of high sensitivity cTnI assays could be helpful for long-term risk stratification of different patient groups, including patients with heart failure or stable coronary artery disease.
At HyTest, we have intensively studied troponin I for over 20 years. Based on this research, we constantly aim to develop improved antibodies from different sources, both hydridoma and recombinant, to be used in the immunoassays that are needed for accurate cardiac disease diagnostics. We have generated and tested recombinant troponins, and troponin secondary and ternary complexes, as well as several monoclonal antibodies and specific to different regions of the cTnI molecule and have tested numerous different MAb combinations to find the best pairs for a precise and sensitive cTnI immunoassay for several platforms.